BioPlus Co Ltd
KOSDAQ:099430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Ferrotec An Hui Technology Development Co Ltd
SZSE:301297
|
CN |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (22.5), the stock would be worth ₩5 690 (1% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.2 | ₩5 630 |
0%
|
| 3-Year Average | 22.5 | ₩5 690 |
+1%
|
| 5-Year Average | 25.1 | ₩6 353.89 |
+13%
|
| Industry Average | 14 | ₩3 555.88 |
-37%
|
| Country Average | 9 | ₩2 274.53 |
-60%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
346.5B KRW | 22.2 | 21.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.4B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 38.5 | 38.7 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.1B CHF | 16.3 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
96.5B DKK | 13.9 | 23.9 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.9B USD | 23.5 | 34 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 12.5 | 33.6 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 20 | -15.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -89.3 | -37.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
868.9B JPY | 21.5 | 49.1 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 13.5 | 22.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.2 |
| Median | 9 |
| 70th Percentile | 16.6 |
| Max | 2 215 132.4 |
Other Multiples
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
